Alex Biese

As part of its Speaking Out video series, CURE® spoke with Upal Basu Roy of LUNGevity about recently approved treatments for lung cancer and what is on the horizon.

As part of its Speaking Out video series, CURE® spoke with Amy C. Moore of LUNGevity about the chemotherapy shortage and its impact on patients with lung cancer.

As part of its Speaking Out video series, CURE® spoke with Amy C. Moore of Lungevity about advancements in treatments for small cell lung cancer.

As part of its Speaking Out video series, CURE® spoke with Brandon Leonard of the LUNGevity Foundation about the role legislation can play in a patient’s cancer journey.

With cyberattacks on medical institutions on the rise, CURE® spoke with an online security expert about steps patients should take if they believe their data has been exposed.

Some patients are forced to deal with “infuriating” attempts at exploitation while navigating their disease.

Artificial intelligence platform ChatGPT is capable of providing “widely understandable and accessible” answers about kidney cancer, but experts express caution.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

The Food and Drug Administration (FDA) has approved Opdivo (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic bladder cancer, the agency has announced.

The Food and Drug Administration approved Besponsa for pediatric patients aged 1 and older with relapsed or refractory CD22-positive, B-cell precursor ALL.

The Food and Drug Administration green lit a first-in-human phase 1 clinical study of Innocell, a vaccine for the treatment of stage 3 and 4 ovarian cancer.

Patients with small cell lung cancer have reasons to be optimistic these days, as one expert explains to CURE.

What advancements for ALK-positive non-small cell lung cancer are on the way, from treating earlier stages of disease to postsurgical options?

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

The Food and Drug Administration has accepted a Biologics License Application for Tevimbra with chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

“The biggest thing that I hate to see happen is that those conversations don't even happen [around cannabis and cancer],” said Dr. Brooke Worster.

Michelle Anderson-Benjamin, who received a diagnosis of metastatic breast cancer in 2022, works as a death doula to provide end-of-life support to patients and their families.

Patients with locally advanced penile squamous cell carcinoma who responded to neoadjuvant chemotherapy followed by consolidative lymphadenectomy experienced improved long-term survival outcomes.

The first patient has been enrolled in a clinical trial evaluating a reduced dose of post-transplant immunosuppressive chemotherapy cyclophosphamide for patients with blood cancers.

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

“We've all been touched by breast cancer in some way. And we need everybody to be a part of this solution,” Kristen Dahlgren told CURE, regarding her decision to be a co-founder of the Pink Eraser Project, before co-founding the Cancer Vaccine Coalition.

Dr. Murugesan Manoharan of Miami Cancer Institute and Baptist Health South Florida shares key questions patients who have received a diagnosis of bladder cancer should ask their care team.

The Food and Drug Administration has approved a reduced dosing frequency of Tecvayli for patients with relapsed or refractory multiple myeloma who have achieved and maintained a complete response or better for at least six months.

Personalized cancer vaccines are on the horizon and could be available for some patient populations as soon as next year, one expert said.

Last week, we saw FDA approvals for new drug regimens, as well as some expert opinion about cancer vaccines

A UCLA neurobiology professor and prostate cancer survivor discuss using artificial intelligence to map his disease and inform treatment decisions.

The Food and Drug Administration has approved Tagrisso plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.

Treatment paradigms may soon be shifting in head and neck cancer, as recent research indicates that lower doses of chemoradiotherapy may be appropriate for some patients.

The Food and Drug Administration approved Tepmetko for adults with metastatic non-small cell lung cancer with MET exon 14 skipping alterations.

Moderna and Merck have initiated V940-001, a phase 3 study evaluating vaccine mRNA-4157 and anti-PD-1 therapy Keytruda as postsurgical treatment for stage 2B to 4 melanoma.